Sleep Apnea Oral Appliances Market - Global Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading
Sleep Apnea Oral Appliances Market
Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Sleep Apnea Oral Appliances Market by Product (Mandibular Advancement Devices (MAD), Tongue-Retaining Devices (TRD)), Purchase Type (Physician-prescribed), Gender (Male, Female), Age Group, Distribution Channel (Online, Retail) - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.
The global sleep apnea oral appliances market is projected to reach USD 0.8 billion by 2030, up from USD 0.5 billion in 2025, with a CAGR of 9.8%
The report discusses market penetration, product development and innovation, market development and diversification, and competitive assessment. In-depth insights into trends, R&D activities, product launches, and assessments of leading market players' growth strategies and revenue are also provided.
This growth is fueled by an increase in lifestyle-related disorders such as diabetes, hypertension, and obesity leading to obstructive sleep apnea. The awareness of managing and treating sleep apnea is rising, alongside innovations by leading companies offering advanced, adjustable oral appliances.
Primary participants include SomnoMed (Australia), Resmed (US), ProSomnus Sleep Technologies (US), and other significant companies like DynaFlex, Vivos Therapeutics, and OpenAirway.
Understanding market dynamics and capturing market share are vital for established and new firms. Those purchasing the report can adopt strategies to enhance market presence. The report offers insights into market drivers (such as the large pool of undiagnosed patients, rising awareness, and increasing usage of oral appliances), restraints, opportunities, and challenges.
End User Dominance: Home Care Settings/Individuals
The home care settings/individuals segment is anticipated to dominate the market. This segment's growth is attributed to the preference for sleep apnea devices due to convenience, remote availability, and cost-efficiency. Insurance and reimbursement policies further enhance this market, particularly in regions like North America and Europe, propelled by lifestyle choices prevalent in these areas. The accessibility of home sleep apnea tests also supports this market expansion.
Distribution Channel Insights: Retail Pharmacies Lead
Retail pharmacies hold the largest market share in this segment due to the increasing availability and establishment of these outlets in emerging markets. The demand for oral appliances is rising as awareness of undiagnosed sleep apnea risks grows. Retail pharmacies offer varied devices with no waiting times, accommodating different affordability and quality preferences.
Regional Growth: Asia Pacific Ascends
The Asia Pacific region is set to grow at the highest CAGR during the forecast period, boasting the fastest-growing market for sleep apnea oral appliances. Manufacturing and distribution companies are expanding their presence, evidenced by new manufacturing plants. Advances in healthcare infrastructure and technology also contribute to this growth.
Key Attributes:
Report Attribute
Details
No. of Pages
265
Forecast Period
2025 - 2030
Estimated Market Value (USD) in 2025
$0.5 Billion
Forecasted Market Value (USD) by 2030
$0.8 Billion
Compound Annual Growth Rate
9.8%
Regions Covered
Global
Market Dynamics
Drivers
Large Pool of Undiagnosed Sleep Apnea Patients
Growing Awareness Associated With Effects of Untreated Sleep Apnea
Increasing Usage of Oral Appliances Among Patients With Mild-to-Moderate Sleep Apnea
Entry of Established Companies With Advanced Sleep Apnea Oral Solutions
Challenges
Complex Referral Pathways and Long Waiting Periods
Opportunities
Rising Demand for At-Home Sleep Apnea Tests
Increasing Importance of Telemedicine, Mhealth, and Ai
Poor Compliance and Low Adherence Associated With Cpap
Company Profiles
Key Players
Somnomed
Resmed
Prosomnus Sleep Technologies
Dynaflex
Vivos Therapeutics, Inc.
Openairway
Panthera Dental
Airway Management
Apnea Sciences
Oravanosa
Myerson Llc.
Braebon Medical Corporation
Other Players
Mpowrx Health & Wellness Products
The Snore Reliever Company, Llc
Tomed Gmbh
The Aurum Group
Erkodent Enrich Kopp Gmbh
Oscimed Sa
Sicat Gmbh & Co. Kg
Glidewell
Apnomed, Inc.
Zquiet
Dream Systems Dental Sleep Lab
Alive Medical Surgical Equipment Trading Llc
Orthoapnea
Doc Brands, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/bjuhjd
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Sleep Apnea Oral Appliances Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Carbon Footprint Management Market Analysis Report and Growth Forecasts 2025-2030, with Profiles of Wolters Kluwer, IBM, Schneider Electric, Dakota Software, ENGIE IsoMetrix, ProcessMAP, SAP and Ecova
The Carbon Footprint Management Market is set to expand from USD 12.04 billion in 2024 to USD 20.44 billion by 2030, at a CAGR of 9.30%. Key drivers include regulatory policies, sustainability goals, and growing investor interest. Cloud solutions lead with over 42% share, and Asia-Pacific dominates with 56% revenue in 2024. Carbon Footprint Management Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Carbon Footprint Management Market Size, Share & Trends Analysis Report by Deployment (On-premise, Cloud), Type, End-use (Energy & Utilities, Manufacturing, Transportation, IT & Telecommunication), and Region with Growth Forecasts, 2025-2030" report has been added to Carbon Footprint Management Market was valued at USD 12.04 billion in 2024, and is projected to reach USD 20.44 billion by 2030, rising at a CAGR of 9.30%.The market drivers influencing carbon footprint management market considerations are multifaceted and include a combination of regulatory policies, consumer demand for sustainable products and services, corporate sustainability goals, and growing investor interest in environmentally responsible investments. Government regulations and international agreements, such as the Paris Agreement, set emission reduction targets and impose penalties for non-compliance, incentivizing businesses to adopt greener practices. Rising awareness of clean energy across the industrial sector and availability of energy-saving certificates in developed countries such as the U.S. and regions such as the European Union are expected to boost the demand for waste heat recovery systems over the forecast period. The supportive policies in countries such as China, India, Japan, and Australia are expected to boost the market growth in Asia-Pacific over the forecast the development of EU and Emissions Performance Standard (EPS) has majorly propelled the carbon footprint management technology penetration in the market. The provision of a cap-and-trade system, which puts a price on carbon emissions is stimulating CCS installations across several industries such as power generation, chemical processing, oil & gas, iron & steel, and others. Carbon Footprint Management Market Report Highlights Cloud held the largest revenue share of over 42% in 2024. One of the primary reasons for the growth of cloud segment are remote access and affordability to the end-users. Enterprise tier has the largest market share in the end-use segment in the market with 39% of the market in 2024. As concerns about climate change and its impacts continue to grow, organizations are implementing emissions control and tracking systems in manufacturing or power generation facilities are large scale. Energy and Utilities accounted for largest market share in the phase system segment in the market with 31% of the market in 2024. The power sector accounted for two-thirds of the emissions growth from the previous year. Due to high emission rates, carbon capture & storage potential is extremely high in coal-fired power plants which is expected to propel the demand for carbon footprint management solution in near future. As of 2024, the Asia-Pacific accounted for 56.0% revenue share in the overall market. Government initiatives by major countries like China, India, Japan and Australia to track and reduce carbon emissions is expected to drive the market over forecast period. Various strategic initiatives were recorded over the past few years to boost the growth of the market. For instance, in May 2023, SAP launched Green ledger solution to tackle carbon footprint management like tracking of carbon in the daily operations. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Key Attributes: Report Attribute Details No. of Pages 120 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $12.04 Billion Forecasted Market Value (USD) by 2030 $20.44 Billion Compound Annual Growth Rate 9.3% Regions Covered Global Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Snapshot2.2. Segmental Outlook2.3. Competitive OutlookChapter 3. Market Variables, Trends, and Scope3.1. Global Carbon Footprint Management Market Outlook3.2. Value Chain Analysis3.3. Technology Overview3.4. Regulatory Framework3.5. Market Dynamics3.6. Porter's Five Forces Analysis3.7. PESTLE AnalysisChapter 4. Carbon Footprint Management Market: Deployment Estimates & Trend Analysis4.1. Carbon Footprint Management Market: Deployment Movement Analysis, 2024 & 20304.2. On Premise4.3. CloudChapter 5. Carbon Footprint Management Market: Type Estimates & Trend Analysis5.1. Carbon Footprint Management Market: Type Movement Analysis, 2024 & 20305.2. Basic Tier5.3. Mid-Tier5.4. Enterprise-TierChapter 6. Carbon Footprint Management Market: End-User Estimates & Trend Analysis6.1. Carbon Footprint Management Market: End-User Movement Analysis, 2024 & 20306.2. Energy & Utilities6.3. Manufacturing6.4. Transportation6.5. IT & Telecommunication6.6. Residential and Commercial BuildingsChapter 7. Carbon Footprint Management Market: Regional Estimates & Trend Analysis7.1. Regional Analysis, 2024 & 2030Chapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, By Key Market Participants8.2. Company Categorization8.3. Heat Map Analysis8.4. Vendor Landscape8.5. Strategy Mapping8.6. Company Profiles Wolters Kluwer IBM Corporation Schneider Electric Dakota Software ENGIE IsoMetrix ProcessMAP Schneider Electric SAP Ecova For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Carbon Footprint Management Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
40 minutes ago
- Yahoo
PTC Inc (PTC) Q3 2025 Earnings Call Highlights: Strong ARR Growth and Strategic Advancements ...
Constant Currency ARR: $2.372 billion, up 9.3% year over year. Free Cash Flow: $242 million, up 14% year over year. Cash and Cash Equivalents: $199 million at the end of Q3. Total Debt: $1.236 billion, with a leverage ratio of 1.2 times. Share Repurchase: $75 million used to repurchase 444,000 shares in Q3. ARR Growth by Region: 8% in the Americas, 11% in Europe, 11% in Asia Pacific. ARR Growth by Product Group: 8% in CAD, 10% in PLM. Guidance for Free Cash Flow: Approximately $850 million for fiscal '25. Q4 Free Cash Flow Guidance: $90 million to $95 million. Fully Diluted Share Count: 121 million in fiscal '24, expected to be flat in fiscal '25. Warning! GuruFocus has detected 7 Warning Sign with PTC. Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PTC Inc (NASDAQ:PTC) reported a 9.3% constant currency ARR growth and a 14% increase in free cash flow year over year, indicating strong financial performance. The company continued to deleverage its balance sheet and repurchase shares, reflecting a solid financial strategy. PTC Inc (NASDAQ:PTC) advanced its product data foundation strategy with enhancements in CAD, PLM, ALM, SLM, and SaaS, including AI-driven features. The company has a strong pipeline for Q4 with several meaningful opportunities across verticals and core products. PTC Inc (NASDAQ:PTC) is seeing positive feedback and validation from customers on its AI strategy, with plans for more AI capabilities in fiscal year '26. Negative Points Policy and trade uncertainty led some customers to slow or face deals, impacting the company's operations. Input costs and tariff discussions remain important watch items, with dynamics differing across verticals and geographies. The company faced churn events in its ServiceMax business, affecting overall growth expectations. FX volatility remains a concern, with significant moves potentially impacting financial results. The macro environment remains dynamic, with ongoing variability and potential downsizing of deals affecting ARR growth. Q & A Highlights Q: Can you provide an update on the go-to-market initiatives and how you're thinking about verticalization and product packaging? A: Neil Barua, CEO, explained that the go-to-market transformation is progressing well, with improvements in win rates and rep productivity. The focus is on building a durable go-to-market engine, with vertical messaging and product portfolio enhancements. Robert Dahdah, CRO, added that foundational work is in place, and vertical messaging is being tested to solve industry-specific problems. Q: What gives you confidence going into Q4, especially regarding the macro outlook? A: Neil Barua, CEO, noted that the pipeline is evolving positively, with the highest number of $5 million-plus deals in the pipeline. The team is focused on maximizing potential and executing deals effectively. The alignment with C-level executives and strategic partnerships, like the one with NVIDIA, are also contributing to confidence in Q4. Q: Are you seeing any changes in behavior due to tariff uncertainty dissipating? A: Kristian Talvitie, CFO, mentioned that while there isn't an all-clear in the market, there is more clarity in customer conversations. Recent agreements and tax policies have provided defined guardrails for manufacturers, leading to more strategic thinking about digital transformation. Q: How is the ServiceMax business progressing, and what is its importance in your go-to-market strategy? A: Neil Barua, CEO, stated that ServiceMax is differentiating Windchill from competitors and is critical for product data foundation. Despite some churn events, the strategic intent of ServiceMax remains strong, and its connection to core products like Windchill and Creo is crucial for AI applications. Q: How do you view commercial optimization as a lever for growth? A: Neil Barua, CEO, and Robert Dahdah, CRO, discussed the opportunity for commercial optimization, emphasizing the need to align with customer value. The team is exploring options to optimize commercial arrangements while ensuring customers see the value in new innovations and offerings. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market" report has been added to global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients' quality of life and achieve clinical remission for the longest period key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products. Report ScopeThe report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class. The IBD therapeutics segment is further segmented based on type and drug class. The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also report includes: 142 data tables and 54 additional tables Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors Insights derived from Porter's Five Forces model, as well as global supply chain analysis Patent analysis, featuring key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc. Key Attributes: Report Attribute Details No. of Pages 155 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $33.3 Billion Forecasted Market Value (USD) by 2030 $52.6 Billion Compound Annual Growth Rate 9.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Inflammatory Bowel Disease Irritable Bowel Syndrome Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market Impact of U.S. Tariffs Macroeconomic Factor Analysis Population Demographics and Aging Populations Government Policies on Drug Prices Chapter 3 Market Dynamics Market Drivers Rising Prevalence of Gastrointestinal Disorders Increasing Entry of Biologics and Biosimilars Market Restraints Side Effects and Ceiling Impact of Biologics Overlap with Other Gi Disorders Use of Alternative Treatment Approaches Market Opportunities Self-Administered Drugs Personalized Therapies Chapter 4 Regulatory Landscape Regulatory Aspects of IBS and IBD Therapeutics The U.S. European Union Asia-Pacific Chapter 5 Emerging Technologies and Pipeline Analysis Key Takeaways Emerging Technologies Novel Target-based Small-Molecule Drugs Microbiome-based Therapeutics Advanced Combination Treatments AI for Drug Discovery Pipeline Analysis Chapter 6 Market Segmentation Analysis Market Analysis by Disease Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Drug Class Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Key Takeaways Industry Structure Company Share Analysis of the IBD Therapeutics Market Competitive Share Analysis of the IBS Therapeutics Market Strategic Analysis Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective Introduction to ESG ESG Risk Ratings Company Profiles Abbvie Inc. Amgen Inc. Astrazeneca Bayer AG Biogen Bristol-Myers Squibb Co. Gilead Sciences Inc. Ironwood Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. UCB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
